Despite its high burden of disease, viral hepatitis B has been long neglected and still receives little public attention and political support as compared to other infectious diseases (e.g HIV, tuberculosis, malaria). Prevention of hepatitis B virus (HBV) mother-to-child transmission (MTCT), a key component to achieve HBV elimination, relies on antiviral therapy of highly viremic HBV-infected pregnant women and HBV vaccination at birth of their babies1. In its elimination plan, the World Health Organisation (WHO) called for a major increase in coverage of vaccination (90%), diagnosis (90%) and treatment (80%) by 2030.